At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,053 enrolled
Drug / intervention
13-valent Pneumococcal Conjugate Vaccine (13vPnC)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, & Reactogenicity of a 13vPnC Vaccine in Ambulatory Elderly Adults Aged 68 Years & Older Who Received 1 or More Doses of 23vPS Vaccine at Least 3 Years Before Study Enrollment
In Brief
A Phase 3 clinical trial evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) for Pneumococcal Infections. Completed, enrolled 1,053 participants across 59 sites in 3 countries.
Detailed Summary
To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study enrollment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Infections
CountriesGermany, Sweden, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2007
Enrollment StartMay 2008
Primary CompletionApr 2009
Study CompletionMay 2009
TodayJul 2026
First PostedJul 11, 2007
Enrollment StartMay 1, 2008
Primary CompletionApr 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.0 years ago
Interventions
13-valent Pneumococcal Conjugate Vaccine (13vPnC)biological